The George Washington University is one of four US sites conducting a Phase I clinical trial to test the safety and immune responses of two mRNA vaccine antigens for HIV on 56 healthy adults. The GW Vaccine Research Unit is running one of the study sites and acting as the processing lab and biorepository. The unit has partnered with study sponsor IAVI on two other HIV vaccine-related Phase I clinical trials and conducted several other clinical vaccine trials, including one for the FDA-authorized COVID-19 vaccine. Continue reading to see more about what GW is doing for the First Human Trial of mRNA-based HIV Vaccine.
GW Participating in the First Human Trial of mRNA-based HIV Vaccine
Latest News
The GW VRU Director, Dr. David Diemert, co-authored an article assessing the value of public health, economic, and societal value of developing a vaccine to prevent and reduce the transmission of Schistosomiasis. Endemic in 78 countries, it is estimated that approximately 236 million people were…
VRU Director, Dr. David Diemert, attends the annual Joint Coordinating Board meeting of TDR (Special Programme for Research and Training in Tropical Diseases) of the WHO in Geneva, Switzerland